[Barbexaclone in the treatment of the epilepsies (author's transl)].

Abstract

Chronic administration of barbiturates in the treatment of the epilepsies causes sedation. The association of C.N.S. stimulant agents appears to offer a possible advantage. 19 epileptic outpatients were followed up during an "open" trial of barbexaclone (L-1-cyclohexyl-2-methylaminopropan-phenyl-ethyl-barbiturate) over a period of about one year. The drug was effective in primary and secondarily generalized epilepsies, and to a lesser extent in partial complex seizures. The tolerability was good and a reduction of the side-effects due to previous treatment with phenobarbitone has been noticed. The mean dosage of barbexaclone was lower in patients who improved than in those who remained unchanged.

• Authors: D Visintini, S Calzetti, D Mancia
• Journal: Rivista di patologia nervosa e mentale (Riv Patol Nerv Ment) 1981 Jan-Feb Vol. 102 Issue 1 Pg. 29-37 ISSN: 0035-6433 [Print] Italy
• Vernacular Title: Il barbexaclone nel trattamento delle epilessie.
• PMID: 7345550 (Publication Type: English Abstract, Journal Article)

Chemical References

• barbexaclone
• Phenobarbital

Topics

• Adolescent
• Adult
• Epilepsy (drug therapy)
• Female
• Humans
• Male
• Middle Aged
• Phenobarbital (analogs & derivatives, therapeutic use)